Magazine Article | December 1, 2020

Phase 2/3 Outsourced Spend By Provider Type

Source: Life Science Leader

By Industry Standard Research

ISR asked respondents responsible for outsourcing Phase 2/3 drug development how they allocate their outsourcing budget toward CROs of various sizes and academic medical centers. As expected, large, full-service CROs received the largest amount, accounting for 57% of outsourced spend overall. In a separate question, respondents were asked to select benefits of each provider type. Respondents selected an average of eight associated benefits for large CROs, about six for midsize and small CROs, and about four for academic medical centers.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: